Previous 10 | Next 10 |
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Edgewise Therapeutics Inc. (EWTX) is expected to report $-0.4 for Q3 2023
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from N...
– Initiating new Phase 2 FOX trial in boys with Duchenne who have been previously treated with gene therapy – – Continuing dose escalation of Phase 2 LYNX trial and initiating a cohort in boys with Duchenne not currently treated with corticosteroids – ...
2023-10-03 17:29:36 ET Gainers: Edgewise Therapeutics ( NASDAQ: EWTX ) +7% . Cantaloupe ( CTLP ) +6% . Computer Programs and Systems ( CPSI ) +6% . REGENXBIO ( RGNX ) +5% . Tandem Diabetes Care ( TNDM ) +5% . Lose...
– Company to host conference symposium to discuss its approach to protecting dystrophic muscle featuring key opinion leaders and 12-month results from the ARCH open label study of EDG-5506 in adults with Becker – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading mus...
– GRAND CANYON is the first pivotal study of an investigational therapy for Becker – – CANYON, the initial Phase 2 cohorts, is fully enrolled – Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today ann...
– EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator that has the potential to benefit a broad spectrum of HCM and other cardiomyopathy patients – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, toda...
2023-08-10 10:11:44 ET Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q2 Non-GAAP EPS of -$0.34. Cash, cash equivalents and marketable securities were approximately $310 million as of June 30, 2023. For further details see: Edgewise Therapeutics Non-GAAP E...
News, Short Squeeze, Breakout and More Instantly...
Edgewise Therapeutics Inc. Company Name:
EWTX Stock Symbol:
NASDAQ Market:
Edgewise Therapeutics Inc. Website:
2024-07-01 09:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-30 19:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...